Business Context and Reporting Period
This Form 8-K reports on a special meeting of stockholders held by Novus Therapeutics, Inc. on December 18, 2020. The filing details the voting results on four proposals and provides a pro forma capitalization table as of December 22, 2020. Note: The input metadata references "Eledon Pharmaceuticals," but the filing text explicitly identifies the registrant as Novus Therapeutics, Inc.
Key Financial Metrics and Capital Structure
The filing does not provide revenue, profit, cash flow, or debt metrics. It focuses on capital structure and equity instruments:
- Outstanding Common Stock: 15,160,397 shares (as of conversion date).
- Outstanding Preferred Stock: 6,003,872 shares (Series X1, presented on an as-converted basis, subject to beneficial ownership blockers).
- Total Outstanding Shares: 21,164,270.
- Outstanding Warrants: 3,425,821 shares with a weighted-average exercise price of $9.02.
- Outstanding Options: 3,627,382 shares with a weighted-average exercise price of $16.42.
- Incentive Plan Reserve: Approximately 4,167,044 shares available for grant under the 2020 Long Term Incentive Plan.
Material Changes and Voting Results
Stockholders approved four key proposals at the Special Meeting:
- Series X1 Preferred Stock Conversion: Approved issuance of common stock upon conversion of Series X1 Preferred Stock.
- For: 499,633 | Against: 654 | Withhold/Abstain: 8,904.
- Note: 214,307 shares issued in the Anelixis Therapeutics acquisition were excluded from the Nasdaq vote tabulation but voted in favor under Delaware law.
- 2020 Long Term Incentive Plan: Approved.
- For: 681,842 | Against: 33,309 | Withhold/Abstain: 8,346.
- Bylaw Amendment (Virtual Meetings): Ratified amendment to allow virtual participation.
- For: 1,064,514 | Against: 2,134 | Withhold/Abstain: 1,010.
- Adjournment Authority: Approved authority to adjourn or postpone the meeting to solicit additional votes.
- For: 971,104 | Against: 59,625 | Withhold/Abstain: 36,929.
Guidance, Risks, and Unusual Items
The filing contains no forward-looking guidance, management commentary on financial performance, or discussion of risks and contingencies. The primary unusual item noted is the application of beneficial ownership conversion blockers, which prevented the full conversion of Series X1 Preferred Stock into common stock at the time of the report, leaving 6,003,872 shares outstanding on an as-converted basis.
Investor Verification Checklist
- Verify the impact of the beneficial ownership conversion blockers on the final dilution from the Series X1 Preferred Stock conversion.
- Confirm the exact number of shares issued upon the full conversion of Series X1 Preferred Stock once blockers are lifted.
- Review the terms of the 2020 Long Term Incentive Plan to understand vesting schedules and potential future dilution from the 4.1 million share reserve.
- Assess the dilution risk from outstanding warrants (weighted avg. $9.02) and options (weighted avg. $16.42) relative to the current market price.